Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML

Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML Professional…


LucidWargames_simulation

In Vivo CAR-T: Stress-Testing the Lilly–Kelonia Deal with AI-Powered Wargaming

Why the Lilly–Kelonia Deal Matters for In Vivo CAR-T Download the…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash

Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas

Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration

Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: MSD to acquire Terns

Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like receptor assets

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million

Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million…


Privacy Preference Center